Pericardial Effusion and Bruton Tyrosine Kinase Inhibitors in B-Cell Malignant Disease

This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes.

Corresponding Author: Ramzi Ibrahim, MD, Department of Cardiovascular Medicine, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259 (ibrahim.ramzi@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.